{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:20:24Z","timestamp":1790716824830,"version":"4.1.0"},"reference-count":127,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA006973"],"award-info":[{"award-number":["P30CA006973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CA A Cancer J Clinicians"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous Reed\u2010Sternberg cells in an inflammatory background. Patients are commonly diagnosed with HL in their 20s and 30s, and they present with supradiaphragmatic lymphadenopathy, often with systemic B symptoms. Even in advanced\u2010stage disease, HL is highly curable with combination chemotherapy, radiation, or combined\u2010modality treatment. Although the same doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapeutic regimen has been the mainstay of therapy over the last 30 years, risk\u2010adapted approaches have helped de\u2010escalate therapy in low\u2010risk patients while intensifying treatment for higher risk patients. Even patients who are not cured with initial therapy can often be salvaged with alternate chemotherapy combinations, the novel antibody\u2010drug conjugate brentuximab, or high\u2010dose autologous or allogeneic hematopoietic stem cell transplantation. The programmed death\u20101 inhibitors nivolumab and pembrolizumab have both demonstrated high response rates and durable remissions in patients with relapsed\/refractory HL. Alternate donor sources and reduced\u2010intensity conditioning have made allogeneic hematopoietic stem cell transplantation a viable option for more patients. Future research will look to integrate novel strategies into earlier lines of therapy to improve the HL cure rate and minimize long\u2010term treatment toxicities.\n                    <jats:bold>CA Cancer J Clin 2018;68:116\u2010132<\/jats:bold>\n                    . \u00a9\n                    <jats:bold>2017 American Cancer Society<\/jats:bold>\n                    .\n                  <\/jats:p>","DOI":"10.3322\/caac.21438","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T14:59:57Z","timestamp":1512140397000},"page":"116-132","source":"Crossref","is-referenced-by-count":355,"title":["Hodgkin lymphoma: A review and update on recent progress"],"prefix":"10.3322","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-6221","authenticated-orcid":false,"given":"Satish","family":"Shanbhag","sequence":"first","affiliation":[{"name":"Assistant Professor of Medicine, Departments of Medicine and Oncology Johns Hopkins University School of Medicine Baltimore MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[{"name":"Director, Division of Hematologic Malignancies and Professor of Oncology, Departments of Medicine and Oncology Johns Hopkins University School of Medicine Baltimore MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/095952873201700106"},{"key":"e_1_2_10_3_1","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_2_10_5_1","volume-title":"SEER Cancer Statistics Review, 1975\u20102014","author":"Howlader N","year":"2017"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.2.462.462"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.2.496.496"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa023141"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-454694"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-10-200805200-00005"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11459"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200301030-00011"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj361"},{"key":"e_1_2_10_14_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_10_16_1","first-page":"1848","article-title":"A clinicopathologic study of 659 cases","volume":"49","author":"Butler T","year":"1981","journal-title":"Cancer"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.6.1595.1595"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.17.970"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.776"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21995"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1548"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19891015)64:8<1686::AID-CNCR2820640822>3.0.CO;2-I"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930315)71:6<2062::AID-CNCR2820710622>3.0.CO;2-0"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851215)56:12<2874::AID-CNCR2820561227>3.0.CO;2-2"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.11.1630"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903040048"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5229"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.4036"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.203.6.392"},{"key":"e_1_2_10_31_1","volume-title":"SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988\u20102001, Patient and Tumor Characteristics. NIH Pub. No. 07\u20106215","author":"Ries LAG","year":"2007"},{"key":"e_1_2_10_32_1","first-page":"1225","article-title":"Evidence for an orderly progression in the spread of Hodgkin's disease","volume":"26","author":"Rosenberg SA","year":"1966","journal-title":"Cancer Res"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1148\/78.4.553"},{"key":"e_1_2_10_34_1","first-page":"1268","article-title":"Extended\u2010field radical radiotherapy in advanced Hodgkin's disease: short\u2010term results of 2 randomized clinical trials","volume":"26","author":"Kaplan HS","year":"1966","journal-title":"Cancer Res"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(85)90357-8"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-73-6-881"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.6.906"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211193272102"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200205023461821"},{"key":"e_1_2_10_41_1","first-page":"799","article-title":"Radiotherapy versus combined modality treatment of stage I and II Hodgkin's disease","volume":"66","author":"Nissen NI","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064601"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000067"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61469-0"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111961"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.9298"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408648"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8018"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5807"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.3239"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.4803"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4817"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5648"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100340"},{"key":"e_1_2_10_55_1","first-page":"CD007941","article-title":"Comparison of first\u2010line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma [serial online]","volume":"5","author":"Skoetz N","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073544"},{"key":"e_1_2_10_57_1","first-page":"35","article-title":"Quality of life and fertility in Hodgkin disease patients treated with escalated BEACOPP","volume":"94","author":"Jurczak W","year":"2009","journal-title":"Haematologica"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6525"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.10.2292.2292"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.06.006"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_10_64_1","first-page":"CD009411","article-title":"High\u2010dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma [serial online]","volume":"6","author":"Rancea M","year":"2013","journal-title":"Cochrane Database Systematic Rev."},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21587"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.3.616"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2069"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8401"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-085159"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1942"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0379"},{"key":"e_1_2_10_79_1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint\u2010blocking antibody side effects [serial online]","author":"Postow MA","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-216228"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0057-1"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.06.025"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.08.014"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-749556"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761346"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738385"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705977"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.332"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703895"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.2415"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3827"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1105370"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.5958"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22762"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.3469"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21303"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.4363"},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.05.005"},{"key":"e_1_2_10_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-541078"},{"key":"e_1_2_10_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665505"},{"key":"e_1_2_10_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.9516"},{"key":"e_1_2_10_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.2069"},{"key":"e_1_2_10_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-078725"},{"key":"e_1_2_10_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-361055"},{"key":"e_1_2_10_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-766121"},{"key":"e_1_2_10_111_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0064"},{"key":"e_1_2_10_112_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.131"},{"key":"e_1_2_10_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532184"},{"key":"e_1_2_10_114_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj017"},{"key":"e_1_2_10_115_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505949"},{"key":"e_1_2_10_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26257"},{"key":"e_1_2_10_117_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1203::AID-CNCR20>3.0.CO;2-2"},{"key":"e_1_2_10_118_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.1.25"},{"key":"e_1_2_10_119_1","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-2-13"},{"key":"e_1_2_10_120_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.2.75"},{"key":"e_1_2_10_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70303-6"},{"key":"e_1_2_10_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2010.03.003"},{"key":"e_1_2_10_123_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.4444"},{"key":"e_1_2_10_124_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.6588"},{"key":"e_1_2_10_125_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-034405"},{"key":"e_1_2_10_126_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108293250902"},{"key":"e_1_2_10_127_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.1989"},{"key":"e_1_2_10_128_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.939"}],"container-title":["CA: A Cancer Journal for Clinicians"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3322%2Fcaac.21438","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.3322\/caac.21438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:53:56Z","timestamp":1762361636000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.3322\/caac.21438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":127,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.3322\/caac.21438"],"URL":"https:\/\/doi.org\/10.3322\/caac.21438","archive":["Portico"],"relation":{},"ISSN":["0007-9235","1542-4863"],"issn-type":[{"value":"0007-9235","type":"print"},{"value":"1542-4863","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}